Skip to main content
SpringerLink
Log in

Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Everolimus-eluting stents (EES; Xience V) are among the most commonly used newer generation drug-eluting stents in clinical practice and have clearly proven superiority over paclitaxel-eluting stents. Nevertheless, the relative merits of EES against the previous gold-standard sirolimus-eluting stent (SES; Cypher) have been less extensively assessed. We aimed to compare the clinical outcomes of EES with SES in patients with coronary artery disease undergoing percutaneous coronary intervention.

Methods and results

We identified eight eligible randomized trials comparing EES with SES including 11,167 patients. The primary endpoint was the incidence of major adverse cardiac events (MACE). Secondary endpoints were target lesion revascularization (TLR) and the composite of definite and probable stent thrombosis. The follow-up ranged from 9 to 36 months. No heterogeneity across the trials was observed regarding the selected endpoints. There was no difference in risk of MACE (HR 0.91 [0.79–1.04]; p = 0.15), TLR (HR 0.86 [0.72–1.04]; p = 0.12) and the composite of definite and probable stent thrombosis (HR 0.84 [0.54–1.29], p = 0.42). The risk of definite stent thrombosis was significantly lower in patients receiving EES (HR 0.49 [0.27 to 0.91]; p = 0.02).

Conclusion

Using the largest available dataset of patients treated in randomized trials, the present meta-analysis demonstrated that the use of EES versus SES was associated with comparable incidence of overall clinical events. However, EES may be associated with a lower risk of definite stent thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zahn R, Hamm CW, Schneider S, Zeymer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Senges J (2007) The sirolimus-eluting coronary stent in daily routine practice in germany: trends in indications over the years. Results from the prospective multi-centre german cypher stent registry. Clin Res Cardiol 96:548–556

    Article  PubMed  CAS  Google Scholar 

  2. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030–1039

    Article  PubMed  CAS  Google Scholar 

  3. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948

    Article  PubMed  CAS  Google Scholar 

  4. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998–1008

    Article  PubMed  CAS  Google Scholar 

  5. de Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A, Schömig A, Kastrati A (2011) Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin Res Cardiol 100:561–570

    Article  PubMed  CAS  Google Scholar 

  6. Dibra A, Tiroch K, Schulz S, Kelbaek H, Spaulding C, Laarman GJ, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA, Schalij MJ, Violini R, Schomig A, Kastrati A (2010) Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol 99:345–357

    Article  PubMed  CAS  Google Scholar 

  7. Kukreja N, Onuma Y, Serruys PW (2009) Xience v everolimus-eluting coronary stent. Expert Rev Med Devices 6:219–229

    Article  PubMed  CAS  Google Scholar 

  8. Wohrle J, Rottbauer W, Imhof A (2011) Everolimus-eluting stents for treatment of chronic total coronary occlusions. Clin Res Cardiol 101:23–28

    Article  PubMed  Google Scholar 

  9. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC (2010) Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (compare): A randomised trial. Lancet 375:201–209

    Article  PubMed  CAS  Google Scholar 

  10. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrie D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the spirit ii trial. Eurointervention 2:286–294

    PubMed  Google Scholar 

  11. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ (2008) Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299:1903–1913

    Article  PubMed  CAS  Google Scholar 

  12. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ (2010) Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362:1663–1674

    Article  PubMed  CAS  Google Scholar 

  13. Schömig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A (2007) A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50:1373–1380

    Article  PubMed  Google Scholar 

  14. de Waha A, Dibra A, Byrne RA, Ndrepepa G, Mehilli J, Fusaro M, Laugwitz KL, Massberg S, Schomig A, Kastrati A (2011) Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv 4:371–377

    Article  PubMed  Google Scholar 

  15. Kimura T: One-year clinical and angiographic outcomes from the reset trial—randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial. Presented at the ESC in August 2011

  16. Burzotta F, Trani C, Todaro D, Mariani L, Talarico GP, Tommasino A, Giammarinaro M, Niccoli G, Porto I, Leone AM, Mongiardo R, Mazzari MA, Schiavoni G, Crea F (2011) Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv 4:327–335

    Article  PubMed  Google Scholar 

  17. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Seung KB, Yang TH, Lee SG, Lee JH, Seong IW, Cheong SS, Lee BK, Lee NH, Lee K, Kim HS, Jeon DS, Kim MK, Nah DY, Tahk SJ, Park SJ (2011) Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized long-des-III (percutaneous treatment of long native coronary lesions with drug-eluting stent-iii) trial. JACC Cardiovasc Interv 4:1096–1103

    Article  PubMed  Google Scholar 

  18. Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schömig A, Mehilli J (2011) Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: three-year outcomes from a randomized clinical trial. J Am Coll Cardiol 58:1325–1331

    Article  PubMed  Google Scholar 

  19. Jensen LO (2010) Sort out 4: a prospective randomized trial of everolimus-eluting stents and sirolimus-eluting stents in patients with coronary artery disease. Presented at the Transcatheter Cardiovascular Therapeutics meeting, September 2010

  20. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La HP, Rocca, Ricard I, Pfisterer M (2010) Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 363:2310–2319

    Article  PubMed  CAS  Google Scholar 

  21. Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, Park DW, Kang SJ, Lee CW, Lee JH, Choi SW, Seong IW, Lee BK, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Park WJ, Kim HS, Chae JK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Choi YJ, Cheong SS, Yang TH, Jang JS, Her SH, Park SJ (2011) Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus: results from essence-diabetes trial. Circulation 124:886–892

    Article  PubMed  CAS  Google Scholar 

  22. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Chun DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS (2012) Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the excellent randomized trial. J Am Coll Cardiol (in press)

  23. Altman DG, Schulz KF (2001) Statistics notes: concealing treatment allocation in randomised trials. BMJ 323:446–447

    Article  PubMed  CAS  Google Scholar 

  24. Juni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46

    Article  PubMed  CAS  Google Scholar 

  25. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351

    Article  PubMed  Google Scholar 

  26. Jensen LO, Thayssen P, Tilsted HH, Ravkilde J, Junker A, Hansen HS, Hansen KN, Pedersen KE, Sorensen HT, Thuesen L, Lassen JF (2010) Rationale and design of a randomized clinical comparison of everolimus-eluting (xience v/promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease. Cardiology 116:73–78

    Article  PubMed  CAS  Google Scholar 

  27. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267

    Article  PubMed  Google Scholar 

  28. Egger M, Smith GD, Altman D (2001) Systematic reviews in health care: metaanalysis in context. BMJ Publishing, London, p 357

    Book  Google Scholar 

  29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  30. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  Google Scholar 

  31. Räber L, Magro M, Stefanini G (2011) Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents. Presented at the ESC in August 2011

Download references

Conflict of interest

Dr. Kastrati reports having received lecture fees from both Abbott and Cordis. No other conflicts of interest are reported.

Author information

Authors and Affiliations

  1. Deutsches Herzzentrum and 1. Med. Klinik, Klinikum rechts der Isar, Technische Universität, Lazarettstr. 36, 80636, Munich, Germany

    Antoinette de Waha, Salvatore Cassese, Robert A. Byrne, Tomohisa Tada, Lamin A. King, Albert Schömig & Adnan Kastrati

  2. Department of Cardiology, Center for Medical Research and Information, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    Duk-Woo Park

  3. Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy

    Francesco Burzotta & Seung-Jung Park

Authors
  1. Antoinette de Waha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salvatore Cassese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Duk-Woo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Burzotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert A. Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomohisa Tada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lamin A. King
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seung-Jung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Albert Schömig
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Adnan Kastrati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoinette de Waha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Waha, A., Cassese, S., Park, DW. et al. Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 101, 461–467 (2012). https://doi.org/10.1007/s00392-012-0414-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-012-0414-8

Keywords

Search

Navigation